Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Graphite One and Lucid Enter into Second Non-Binding Supply Agreement (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Cipher Pharmaceuticals Inc
T.CPH
Alternate Symbol(s):
CPHRF
Healthcare
Biotechnology
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology...
products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:CPH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Next
(6156)
•••
retiredcf
X
Post by
retiredcf
on Sep 18, 2023 1:23pm
Ink Research
Morning Report: Cipher Pharmaceuticals makes its mark in the INK Top 40 September 18, 2023 Cipher Pharmaceuticals (CPH) stock has been on a steady rise over the past year,
...more
(6156)
•••
retiredcf
X
Post by
retiredcf
on Sep 18, 2023 1:21pm
Ryan Irvine
He and his partner (Aaron Dunn) made their annual appearance at the Toronto MoneyShow on 8 Feb. For those who are unfamiliar with them, their firm (Keystone Financial) analyses over 4000
...more
QIMC and QMET Expand Hydrogen Development with Phase 2 Program
posted Jun 11, 2025 9:00am by
Q Precious & Battery Metals Corp.
-
|
Richard Penn, CEO of QMET, stated: "This phase represents a pivotal advancement for QMET as we deepen our strategic collaboration with QIMC and leverage their advanced proprietary exploration techniques to identify and confirm natural hydrogen zones. Our partnership is driving forward a significant opportunity for Nova Scotia’s energy future and reinforcing its role in Canada’s evolving energy landscape." ...read more
(14)
•••
drewmumaw
X
Comment by
drewmumaw
on Aug 29, 2023 4:38pm
RE:Adieu
Adieu Monsieur. I’ve appreciated your input over the years on this board. Hopefully, you come back in the future. I agree with your general overview regarding Cipher’s declining business. I continue
...more
(99)
•••
Northforce13
X
Post by
Northforce13
on Aug 29, 2023 9:40am
Adieu
I bid you all "adieu" fellow CPH investors, it's been a fantastic fun ride :-) CPH remains a good stock at a decent price, but no longer a great bargain, so I have taken my winnings off
...more
(99)
•••
Northforce13
X
Comment by
Northforce13
on Aug 07, 2023 11:10am
RE:RE:Cipher Partner, Moberg Pharma Announces Approval for MOB-015
The U.S. requires two phase 3 studies for approval. EU does not, if I remember correctly Moberg is taking advantage of the second phase 3 to try using a shorter treatment period, allowing more
...more
(14)
•••
drewmumaw
X
Comment by
drewmumaw
on Jul 21, 2023 10:51am
RE:Cipher Partner, Moberg Pharma Announces Approval for MOB-015
I find it a bit odd that the nail whitening issue requires an additional phase 3 trial to gain approval in the US and Canada, but the European Union approved it regardless. The purpose of this
...more
(190)
•••
Daudau11
X
Post by
Daudau11
on Jul 05, 2023 8:01am
Cipher Partner, Moberg Pharma Announces Approval for MOB-015
Cipher Partner, Moberg Pharma Announces Approval for MOB-015 in the European Union T.CPH | 57 minutes ago Significant regulatory milestone
...more
(0)
•••
evenhand
X
Comment by
evenhand
on Jul 04, 2023 1:06pm
RE:SCD Interview on YouTube
Almost the same story as in the run up of a few years back. "They are ready to grow". I have held some shares since then just to see if I can get some of my money back. A hobby
...more
(1)
•••
GJS471
X
Comment by
GJS471
on Jul 01, 2023 11:49am
RE:RE:RE:RE:RE:CPH: Outperformer, Give Credit When Credit Is Due
The compensation numbers speak for them selves. As for the roles they play, I think they better start playing them soon. Here are the numbers for the Q1 report regarding compensation
...more
(5)
•••
PitchinPennies
X
Comment by
PitchinPennies
on Jun 27, 2023 11:48am
RE:RE:RE:RE:CPH: Outperformer, Give Credit When Credit Is Due
There's high priced talent in the office? How did I miss this? Last time I looked it was just Craig and the coffee boy and maybe a couple of fart-catchers.
(190)
•••
Daudau11
X
Post by
Daudau11
on May 26, 2023 2:58pm
SCD Interview on YouTube
Cipher Pharmaceuticals (TSX: CPH) Update with CEO Craig Mull - YouTube
(1)
•••
GJS471
X
Comment by
GJS471
on Mar 23, 2023 12:42pm
RE:RE:RE:CPH: Outperformer, Give Credit When Credit Is Due
I view the results as rather dismal. Cash to invest but no apparent plans and no reliable track record for doing so successfully. I have been an investor for a very long time and was
...more
(14)
•••
drewmumaw
X
Comment by
drewmumaw
on Mar 23, 2023 10:42am
RE:RE:CPH: Outperformer, Give Credit When Credit Is Due
I listened to the Q4 call. Revenue continues to dry up. MOB-015 and CF-101 are a minimum of 9 months and 12 months out, respectively. The only thing they have going for them is their big pile of cash
...more
(1)
•••
GJS471
X
Comment by
GJS471
on Mar 09, 2023 10:01am
RE:CPH: Outperformer, Give Credit When Credit Is Due
As we approach another quarterly earnings announcement, I just wanted to say that as a long time investor, my numbers are not yours. It has been what I classify as a "faith" investment
...more
(1)
•••
GJS471
X
Comment by
GJS471
on Feb 12, 2023 6:57am
RE:RE:No release date yet for Q4 and Full yr 2022 results
My apologies. You are very correct.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Graphite One and Lucid Enter into Second Non-Binding Supply Agreement
Graphite Creek Project Approved for FAST-41 Federal Permitting Dashboard
Merger Announced to Create a Leading Yukon Copper-Gold Exploration and Development Company